IDEAYA Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 124
- Market Cap
- $3.3B
- Website
- http://www.ideayabio.com
- Introduction
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by...
IDEAYA Biosciences Unveils IDE892, Breakthrough Cancer Drug Candidate with Promising
IDEAYA Biosciences nominates IDE892, a best-in-class MTA-cooperative PRMT5 inhibitor, for development, with IND-enabling studies ongoing and targeting IND-filing in mid-2025.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences granted 170,000 non-qualified stock options to a new employee on December 2, 2024, under the 2023 Inducement Plan, with an exercise price of $27.45 per share and a 10-year term, vesting over four years.
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor
IDEAYA Biosciences announces participation in Citi’s 2024 Global Healthcare Conference on Dec 3rd at 8:00 AM ET and the 7th Annual Evercore HealthCONx Conference on Dec 4th at 1:20 PM ET, featuring CEO Yujiro S. Hata in fireside chats.
IDEAYA Biosciences to Present at Major Healthcare Conferences in December
IDEAYA Biosciences announces participation in Citi's 2024 Global Healthcare Conference on Dec 3rd and Evercore's 7th Annual HealthCONx Conference on Dec 4th, featuring CEO Yujiro S. Hata in fireside chats. Webcasts available at https://ir.ideayabio.com/events.
Cancer researcher highlights 'myths and misconceptions' patients have about trials
Wasif Saif, MD, MBBS, addresses common misconceptions about cancer clinical trials, emphasizing that patients receive active treatment, not placebos, in phase 1 trials and that participation involves personalized care and close monitoring.
Hexagon Bio Appoints Yujiro Hata to Board of Directors
Hexagon Bio appoints Yujiro Hata to its Board of Directors, leveraging his expertise in oncology to advance its pipeline of novel ADCs with next-generation natural product-based payloads for cancer treatment.
IDEAYA Names Stu Dorman as New Chief Commercial Officer
IDEAYA Biosciences appoints Stu Dorman as chief commercial officer to lead transition to commercial launch. Dorman's experience includes global product commercialization at Gilead Sciences. IDEAYA also nominates IDE034, a first-in-class B7H3/PTK7 topo-I-payload biospecific antibody drug conjugate, as a development candidate.
© Copyright 2024. All Rights Reserved by MedPath